BERLIN, May 9 (Xinhua) -- Revenues of German vaccine developer BioNTech in the first quarter (Q1) of 2022 more than tripled year-on-year to 6.4 billion euros (6.7 billion U.S. dollars), the company said on Monday.
The increase was "mainly due to increased commercial revenues from the supply and sales of the company's COVID-19 vaccine worldwide," BioNTech said in a statement. Net profit rose to 3.7 billion euros in Q1, compared to 1.13 billion euros in the same period last year.
"During the first quarter, we demonstrated continued execution across our growth pillars in addressing infectious diseases and oncology," said Ugur Sahin, CEO and Co-Founder of BioNTech. "We have enhanced our COVID-19 vaccine leadership."
BioNTech and Pfizer billed for around 750 million of their COVID-19 vaccine doses in Q1. By the end of April, the companies had signed supply agreements for around 2.4 billion vaccine doses in 2022, according to the statement.
For 2022, BioNTech reaffirmed COVID-19 vaccine revenues of 13 to 17 billion euros. BioNTech and Pfizer are evaluating follow-on versions of the COVID-19 vaccine, including an Omicron-based candidate and bivalent vaccines targeting Omicron as well as other SARS-CoV-2 strains.
